Industry
Biotechnology
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.
Loading...
Open
0.12
Mkt cap
14M
Volume
7.5M
High
0.15
P/E Ratio
-0.85
52-wk high
1.79
Low
0.12
Div yield
N/A
52-wk low
0.10
Portfolio Pulse from Benzinga Newsdesk
July 16, 2024 | 8:50 pm
Portfolio Pulse from Benzinga Newsdesk
June 04, 2024 | 12:23 pm
Portfolio Pulse from Benzinga Insights
May 29, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 9:28 pm
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 7:12 pm
Portfolio Pulse from Benzinga Newsdesk
April 25, 2024 | 12:42 pm
Portfolio Pulse from Benzinga Newsdesk
April 01, 2024 | 8:34 pm
Portfolio Pulse from Benzinga Insights
April 01, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
April 01, 2024 | 12:39 pm
Portfolio Pulse from Benzinga Newsdesk
April 01, 2024 | 10:18 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.